Sirnaomics
圣诺医药
Executive Summary
Sirnaomics is a dual-headquartered (Guangzhou/Gaithersburg) RNA therapeutics company focused on siRNA drug development, trading on NASDAQ as SIRN. The company maintains clear BIOSECURE status, positioning it favorably for US partnerships amid growing China-related regulatory scrutiny. With operations spanning both markets, Sirnaomics represents a potential bridge for cross-border collaborations in the expanding RNAi therapeutic space, though limited public disclosure on recent corporate activities suggests careful due diligence will be essential.
Structure: As a NASDAQ-listed entity with dual headquarters in China and the US, Sirnaomics likely operates through a complex holding company structure typical of US-listed Chinese biotechs, potentially including VIE arrangements for Chinese operations. The dual-jurisdiction setup suggests sophisticated regulatory navigation capabilities but will require thorough mapping of subsidiary relationships and IP ownership structures during due diligence.
Clinical Trials(12 total)
3
Phase 2
5
Phase 1
4
Phase 1, Phase 2
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05196373 | STP705 | Ph.1, Ph.2 | UNKNOWN | 50 |
| NCT05844293 | FXI-GalNAc-siRNA, Placebo | Ph.1 | RECRUITING | 40 |
| NCT05421013 | STP705 | Ph.1, Ph.2 | COMPLETED | 9 |
| NCT05422378 | STP705 | Ph.1 | COMPLETED | 8 |
| NCT05309915 | STP707 | Ph.1 | COMPLETED | 20 |
| NCT05037149 | STP707 | Ph.1 | ACTIVE NOT RECRUITING | 50 |
| NCT04844983 | STP705, Placebo Saline | Ph.2 | COMPLETED | 44 |
| NCT04844840 | STP705, Placebo | Ph.2 | COMPLETED | 29 |
| NCT04676633 | STP705 | Ph.1 | COMPLETED | 5 |
| NCT04669808 | STP705 | Ph.2 | COMPLETED | 32 |
| NCT04293679 | STP705 | Ph.1, Ph.2 | COMPLETED | 25 |
| NCT02956317 | STP705, Placebo | Ph.1, Ph.2 | COMPLETED | 25 |
BIOSECURE Risk
Company maintains clear BIOSECURE status with no BCC designation, indicating current compliance with US regulatory requirements
Key Exposures:
- •Guangzhou headquarters creates ongoing China nexus
- •Potential supply chain dependencies in China
- •Cross-border data transfer requirements for clinical operations
Mitigation: US presence in Gaithersburg suggests proactive approach to maintaining US market access, though specific mitigation strategies not publicly disclosed
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent out-licensing deals recorded in available data
Approach: Approach with cautious optimism focusing on technology assessment and regulatory pathway clarity; prioritize understanding of IP ownership and manufacturing strategy given dual-jurisdiction operations
Red Flags
- ⚠Limited public disclosure of recent corporate activities
- ⚠No visible management team information
- ⚠Unclear subsidiary structure
- ⚠Lack of recent deal-making track record
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 12
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (12 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.